TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia Repair


MALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that additional data from its BRAVO study were presented virtually as posters at the Americas Hernia Society Annual Meeting.

See original here:
TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia Repair

Related Posts